1. Home
  2. LCTX vs RDIB Comparison

LCTX vs RDIB Comparison

Compare LCTX & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

N/A

Current Price

$0.79

Market Cap

251.4M

Sector

Health Care

ML Signal

N/A

Logo Reading International Inc Class B

RDIB

Reading International Inc Class B

SELL

Current Price

$12.46

Market Cap

241.9M

ML Signal

SELL

Company Overview

Basic Information
Metric
LCTX
RDIB
Founded
1990
1937
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Movies/Entertainment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
251.4M
241.9M
IPO Year
1996
1994

Fundamental Metrics

Financial Performance
Metric
LCTX
RDIB
Price
$0.79
$12.46
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
★ $5.50
N/A
AVG Volume (30 Days)
★ 2.1M
4.2K
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 60.76
EPS
★ N/A
N/A
Revenue
$14,556,000.00
★ $202,988,000.00
Revenue This Year
$4.38
$15.10
Revenue Next Year
$10.80
$4.04
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 53.24
N/A
52 Week Low
$0.77
$8.00
52 Week High
$1.99
$24.00

Technical Indicators

Market Signals
Indicator
LCTX
RDIB
Relative Strength Index (RSI) 34.81 52.46
Support Level N/A $10.29
Resistance Level $1.16 $12.59
Average True Range (ATR) 0.08 0.84
MACD -0.03 0.27
Stochastic Oscillator 2.86 92.27

Price Performance

Historical Comparison
LCTX
RDIB

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

About RDIB Reading International Inc Class B

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

Share on Social Networks: